Jeena Sikho Lifecare Limited
₹333.70-₹14.00 (-4.0%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹8,968 Cr
- P/E
- 58.2x
- EV / EBITDA
- 90.3x
- Revenue
- ₹469 Cr
- Net margin
- 21.3%
- ROCE
- 48.2%
Price chart
Technical chartScreen technicals →-55.3% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- -33.7%
- 3M
- -41.1%
- 6M
- -50.6%
- 1Y
- -55.3%
- 5Y
- -52.9%
52-week range
Day change -₹14.00 (-4.0%) from ₹348 to ₹334 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in JSLL, bought on each weekday since 2025.
AI Summary
Indian StockStrengths1
- Strong 5-year revenue CAGR of 28.1%
Concerns1
- Negative free cash flow (₹1 Cr)
Rule-based from financial data. Not advice.
About the company
Jeena Sikho Lifecare Limited trades in ayurvedic medicines in India. The company offers ayurvedic products under the Shuddhi brand name. It also provides services, including in-patient, out-patient, 72 hours health camps, Panchakarma therapies, dietary support and nutrition guidance, home-based healthcare services, and healthcare support centre services.
Read moreShow less
Jeena Sikho Lifecare Limited trades in ayurvedic medicines in India. The company offers ayurvedic products under the Shuddhi brand name. It also provides services, including in-patient, out-patient, 72 hours health camps, Panchakarma therapies, dietary support and nutrition guidance, home-based healthcare services, and healthcare support centre services. In addition, the company operates clinics under the Shuddhi Ayurveda, Shuddhi Clinics, Hospital & Institution of Integrated Medical Sciences, Shuddhi Wellness Clinics & Hospital, Shuddhi Ayurveda Panchakarma Hospital, and Shuddhi Panchakarma Day Care Clinic names. Jeena Sikho Lifecare Limited was founded in 2009 and is headquartered in Zirakpur, India.
- Sector
- Healthcare
- Shares outstanding
- 12.5 Cr shares
- ISIN
- INE0J5801029
- BSE code
- 544476
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹8,968 Cr
- P/E
- 58.2x
- P/B
- 25.2x
- EV / EBITDA
- 90.3x
- EV / Sales
- 27.6x
- P/S
- 27.7x
- Earnings yield
- 1.7%
- 52-week high
- ₹794.70
- 52-week low
- ₹333.70
Profitability
- Operating margin
- 28.7%
- Net margin
- 21.3%
- EBITDA margin
- 30.6%
- ROE
- 35.9%
- ROCE
- 48.2%
- ROA
- 31.2%
- Dividend payout
- 17.0%
- Tax rate
- 26.0%
- Other income, % of PBT
- 6.4%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹469 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 44.8%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 28.1%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹99.0 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 106.3%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 31.9%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 63.0%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹37.0 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 117.6%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹15.0 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 46.4%
Solvency and efficiency
- Current ratio
- 5.36
- Debt / Equity
- 0.01
- Debt / Assets
- 0.00
- Debt / EBITDA
- 0.01
- Financial leverage
- 1.15
- CFO / Net profit
- 0.54
- Cash / Market cap
- 1.6%
- Cash per share
- ₹11.67
- Asset turnover
- 1.47
- Fixed asset turnover
- 4.84
- Capital intensity
- 0.21
- Debtor days
- 46 days
- Inventory turnover
- 3.02
- Cash conversion cycle
- 92 days
Where the revenue went
Some FY2025 lines are not reported, so the ones that are appear as a table.
| Line | FY2025 |
|---|---|
| Sales | ₹469 Cr |
| Expenses | ₹344 Cr |
| Operating profit | ₹125 Cr |
| Other income | ₹6 Cr |
| Interest | ₹1 Cr |
| Depreciation | ₹9 Cr |
| Profit before tax | ₹122 Cr |
| Tax and other | ₹31 Cr |
| Net profit | ₹91 Cr |
Revenue and net profit
Revenue grew 44.8% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹136 Cr | ₹10 Cr |
| FY2022 | ₹146 Cr | ₹11 Cr |
| FY2023 | ₹204 Cr | ₹34 Cr |
| FY2024 | ₹324 Cr | ₹69 Cr |
| FY2025 | ₹469 Cr | ₹91 Cr |
Cash flows
FY2025: ₹69.0 Cr from operations, -₹1.00 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹18 Cr | ₹10 Cr |
| FY2022 | ₹17 Cr | -₹3 Cr |
| FY2023 | ₹17 Cr | -₹40 Cr |
| FY2024 | ₹37 Cr | ₹19 Cr |
| FY2025 | ₹69 Cr | -₹1 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹469 Cr+44.8%1Y
- Net profit
- ₹91 Cr+31.9%1Y
- Cash from operations
- ₹69 Cr
- Free cash flow
- -₹1 Cr-105.3%1Y
- Revenue CAGR, 5Y
- 28.1%
- EBITDA CAGR, 5Y
- 52.5%
- Net profit CAGR, 5Y
- 63.0%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹469 Cr | ₹125 Cr | — | ₹91 Cr | ₹69 Cr | -₹1 Cr | 33.3% | +44.8% | +31.9% |
Monthly returns
Month-by-month returns of JSLL across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹328 Cr |
| Equity capital | ₹25 Cr |
| Reserves | ₹248 Cr |
| Borrowings | ₹11 Cr |
| Other liabilities | ₹45 Cr |
| Assets | ₹328 Cr |
| Fixed assets | ₹153 Cr |
| Capital work in progress | ₹13 Cr |
| Investments | ₹4 Cr |
| Other assets | ₹159 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
JSLL trades at 58.2x earnings against a peer median of 52.6x (a 11% premium).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Jeena Sikho Lifecare LimitedJSLLthis companyP/E ↑ premium | ₹8,968 Cr | 58.2x | 25.2x | 35.9% | 90.3x |
| JYOTHY LABS LIMITEDJYOTHYLAB | ₹9,555 Cr | 27.2x | 6.6x | 32.4% | 17.6x |
| HealthCare Global Enterprises LimitedHCG | ₹9,408 Cr | 513.0x | 8.0x | 2.8% | 49.9x |
| Sanofi India LtdSANOFI | ₹9,387 Cr | 25.4x | 12.0x | — | — |
| PROCTER & GAMBLE HEALTH LIMITEDPGHL | ₹8,946 Cr | 29.2x | 14.4x | — | — |
| Jupiter Life Line Hospitals LimitedJLHL | ₹8,877 Cr | 46.3x | 5.9x | 12.2% | 34.5x |
| Corona Remedies LimitedCORONA | ₹8,749 Cr | 55.1x | — | 18.8% | 55.0x |
| Blue Jet Healthcare LimitedBLUEJET | ₹8,659 Cr | 24.6x | 6.9x | 19.4% | 34.4x |
| STRIDES PHARMA SCIENCE LIMITEDSTAR | ₹8,552 Cr | 112.0x | 2.7x | 1.3% | 35.5x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
JSLL since 1 January, against earlier years.
Historical volatility
JSLL's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 13.0% |
| FY2022 | 12.0% |
| FY2023 | 23.0% |
| FY2024 | 29.0% |
| FY2025 | 27.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹469 Cr |
| Costs | |
| Interest | ₹1 Cr |
| Expenses | ₹344 Cr |
| Operating profitOperating Profit | ₹125 Cr |
| Other income and charges | |
| Profit before tax | ₹122 Cr |
| Tax | |
| Net profitNet Profit | ₹91 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹328 Cr |
| Equity capitalEquity Capital | ₹25 Cr |
| Reserves | ₹248 Cr |
| Borrowings | ₹11 Cr |
| Other liabilitiesOther Liabilities | ₹45 Cr |
| AssetsTotal Assets | ₹328 Cr |
| Fixed assetsFixed Assets | ₹153 Cr |
| Capital work in progressCWIP | ₹13 Cr |
| Investments | ₹4 Cr |
| Other assetsOther Assets | ₹159 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹69 Cr |
| Investing cash flowCash from Investing Activity | -₹70 Cr |
| Financing cash flowCash from Financing Activity | -₹1 Cr |
| Change in cashNet Cash Flow | -₹2 Cr |
Learn while you research
Academy chapters picked for Jeena Sikho Lifecare Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 58.2, learn when high multiples are justified.6 min read
- 04 Growth Investing45% revenue growth is in the top tier, learn how to value growth.7 min read
- 05 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 06 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read